← Back to Search

Mitotic Inhibitor

Paclitaxel for Lung Cancer

Phase 2

Waitlist Available

Research Sponsored by University of Wisconsin, Madison

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Performance status ECOG 0-1

Hepatic: Bilirubin no greater than 2.0 mg/dL, AST no greater than 5 times upper limit of normal

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying how well paclitaxel works in treating patients with non-small cell lung cancer that has returned or does not respond to previous treatment.

Who is the study for?

This trial is for adults over 18 with recurrent or refractory non-small cell lung cancer who've had progressive disease after first-line chemotherapy. They must have adequate kidney, liver, and bone marrow function, controlled brain metastases if present, no significant heart rhythm problems, and not be experiencing severe neuropathy. Participants need to use effective contraception.Check my eligibility

What is being tested?

The study is testing the effectiveness of a chemotherapy drug called paclitaxel in patients with non-small cell lung cancer that has come back or didn't respond to initial treatment. It's a Phase II trial which means it focuses on the drug's efficacy and side effects at different doses.See study design

What are the potential side effects?

Paclitaxel can cause side effects like low blood cell counts leading to increased infection risk and bleeding issues, allergic reactions during infusion, nerve damage resulting in numbness or pain (neuropathy), muscle and joint pain, nausea, vomiting, hair loss, and fatigue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am fully active or can carry out light work.

Select...

My liver function tests are within the required range.

Select...

I don't have serious slow heart rhythm problems.

Select...

I am over 18 years old.

Select...

My kidney function is normal, with creatinine levels at or below 1.5 mg/dL or clearance above 60 mL/min.

Select...

My lung cancer has come back or isn't responding to treatment.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Wisconsin, MadisonLead Sponsor

1,182 Previous Clinical Trials

3,167,387 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,932,461 Total Patients Enrolled

Joan H. Schiller, MDStudy ChairUniversity of Wisconsin, Madison

5 Previous Clinical Trials

935 Total Patients Enrolled

Media Library

Paclitaxel (Mitotic Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT00004265 — Phase 2

Lung Cancer Clinical Trial 2023: Paclitaxel Highlights & Side Effects. Trial Name: NCT00004265 — Phase 2

Paclitaxel (Mitotic Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00004265 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are patients currently being enrolled in this study?

"The latest information from clinicaltrials.gov indicates that this particular trial is not recruiting patients at this time. It was originally posted on February 1st, 1999 but has since been edited on December 3rd, 2013. Even though this study isn't looking for new participants, there are 2,101 other trials that currently are."

Answered by AI

Could you please walk me through the risks associated with this treatment?

"Since this is only a Phase 2 trial, there is not yet clinical evidence to support the efficacy of this treatment. However, it received a score of 2 because there is data suggesting that it is safe."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Paclitaxel in Treating Patients With Recurrent or Refractory Non-small Cell Lung Cancer

1999. "Paclitaxel in Treating Patients With Recurrent or Refractory Non-small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00004265.

All > Acl > Sclc